{"id":7384,"date":"2025-04-10T09:06:25","date_gmt":"2025-04-10T09:06:25","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7384"},"modified":"2025-04-10T09:06:25","modified_gmt":"2025-04-10T09:06:25","slug":"research-group-of-innovative-diagnostic-and-therapeutical-developments-in-solid-tumors-indest","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/que-hacemos\/areas\/oncologia\/research-group-of-innovative-diagnostic-and-therapeutical-developments-in-solid-tumors-indest\/","title":{"rendered":"Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors &#8211; InDeST"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container fusion-parallax-none nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ededed;background-image: url(&quot;https:\/\/www.incliva.es\/wp-content\/uploads\/2021\/01\/fondo.jpg&quot;);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><h3>Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors &#8211; InDeST<\/h3>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-2\" style=\"transform:translate3d(0,0,0);\"><h5><span style=\"color: #3D44AC;\">Oncology Area<\/span><\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-3\" style=\"transform:translate3d(0,0,0);\"><div>\n<!--objetivosgrupo--><br \/>\n Our group aims to improve the patient&#8217;s life through the development of new diagnostic and therapeutic methods. In addition to this main goal, we intend to implement strategies to facilitate the development of precision medicine in solid tumors with innovative therapeutic approaches and provide knowledge on how to approach precision medicine in colorectal and gastric cancer from different points such as molecular classification, the use of predictive biomarkers and new therapeutic approaches<br \/>\n<!--objetivosgrupo fin-->\n<\/div>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:75% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 2.56%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 2.56%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:75% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;border-width: 0 0 0 2px;border-color:#9da0d2;border-style:solid;padding: 4% 4% 4% 4%;\">\n<div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border-radius:5px;\"><img src=\"\/wp-content\/uploads\/2022\/10\/Andres-Cervantes-Ruiperez_FIH14.jpg\" class=\"img-responsive\"\/><\/span><\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;\"><\/div>\n<div class=\"fusion-text fusion-text-4\" style=\"transform:translate3d(0,0,0);\"><h5 class=\"titulo-coordinador\" style=\"text-align: center;\">Coordinator<\/h5>\n<div class=\"nombre-coordinador\" style=\"text-align: center;\">Dr. Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<a class=\"link extra_email\" href=\"mailto:andres.cervantes@uv.es\">andres.cervantes@uv.es<\/a><\/p>\n<a class=\"fb-icon-element-1 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:32px;margin-right:16px;\" href=\"\/en\/andres-cervantes-ruiperez\/\" aria-label=\"Link to \/en\/andres-cervantes-ruiperez\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-1{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-1:hover { color: #9da0d2;}<\/style><\/div>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 4% !important;padding-right : 4% !important;margin-right : 7.68%;padding-bottom : 4% !important;padding-left : 4% !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-1{width:25% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-fullwidth.fusion-builder-row-1 { overflow:visible; }.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-5\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">RESEARCHERS<\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:100% !important;margin-top : 10px;margin-bottom : 20px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-2{width:100% !important;order : 0;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;order : 0;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-6\" style=\"transform:translate3d(0,0,0);\"><h5>Leading, R4<\/h5>\n<p>Andr\u00e9s Cervantes Ruip\u00e9rez &nbsp;&nbsp;&nbsp;<a class=\"fb-icon-element-2 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:21px;margin-right:10.5px;\" href=\"\/en\/andres-cervantes-ruiperez\/\" aria-label=\"Link to \/en\/andres-cervantes-ruiperez\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-2{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-2:hover { color: #9da0d2;}<\/style><\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-3{width:25% !important;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-7\" style=\"transform:translate3d(0,0,0);\"><h5>Established, R3<\/h5>\n<p>Javier Hern\u00e1ndez Gil &nbsp;&nbsp;&nbsp;<a class=\"fb-icon-element-3 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:21px;margin-right:10.5px;\" href=\"\/en\/javier-hernandez-gil\/\" aria-label=\"Link to \/en\/javier-hernandez-gil\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-3{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-3:hover { color: #9da0d2;}<\/style><\/br>Gerardo L\u00f3pez Rodas<\/br>Desamparados Roda P\u00e9rez<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-4{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-4 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-4{width:25% !important;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-4{width:100% !important;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-8\" style=\"transform:translate3d(0,0,0);\"><h5>Recognised\/Emerging, R2<\/h5>\n<p>Valentina Gambardella &nbsp;&nbsp;&nbsp;<a class=\"fb-icon-element-4 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:21px;margin-right:10.5px;\" href=\"\/en\/valentina-gambardella\/\" aria-label=\"Link to \/en\/valentina-gambardella\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-4{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-4:hover { color: #9da0d2;}<\/style><\/br>Susana Rosell\u00f3 Keranen<\/br>Noelia Tarazona Llavero &nbsp;&nbsp;&nbsp;<a class=\"fb-icon-element-5 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:21px;margin-right:10.5px;\" href=\"\/en\/noelia-tarazona-llavero\/\" aria-label=\"Link to \/en\/noelia-tarazona-llavero\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-5{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-5:hover { color: #9da0d2;}<\/style><\/br>Marisol Huerta \u00c1lvaro<\/br>M\u00aa Carolina Mart\u00ednez Ciarpaglini<\/br>Jose A. P\u00e9rez Fidalgo<\/br>Jorge Mart\u00edn Arana<\/br>Gema Bruixola Campos<\/br>Francisco Gimeno Valiente<\/br>Clara Alfaro Cervell\u00f3<\/br>Amelia Insa Moll\u00e1<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-5{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-5 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-5{width:25% !important;}.fusion-builder-column-5 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-5{width:100% !important;}.fusion-builder-column-5 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-9\" style=\"transform:translate3d(0,0,0);\"><h5>First Stage, R1<\/h5>\n<p>Raquel Herrero Tejedor<\/br>Paloma Mart\u00edn Martorell<\/br>Blanca Garc\u00eda Mic\u00f3<\/br>Bel\u00e9n Mart\u00ednez Castedo<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-6{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-6 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-6{width:25% !important;}.fusion-builder-column-6 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-6{width:100% !important;}.fusion-builder-column-6 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 0px;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-10\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">STAFF<\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-7{width:100% !important;margin-top : 10px;margin-bottom : 20px;}.fusion-builder-column-7 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-7{width:100% !important;order : 0;}.fusion-builder-column-7 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-7{width:100% !important;order : 0;}.fusion-builder-column-7 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-11\" style=\"transform:translate3d(0,0,0);\"><h5>Collaborating Researchers<\/h5>\n<p>V\u00edctor Segui Manzaneque<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-8{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-8 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-8{width:25% !important;}.fusion-builder-column-8 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-8{width:100% !important;}.fusion-builder-column-8 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-12\" style=\"transform:translate3d(0,0,0);\"><h5>Nurse<\/h5>\n<p>Silvia Moreno Magraner<\/br>Mar\u00eda Montes de Oca Ortu\u00f1o<\/br>Mar\u00eda Isabel Calzadilla Luz<\/br>Inma Blasco Blasco<\/br>Gloria Corredor Agull\u00f3<\/br>Ana Ruiz Qu\u00edlez<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-9{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-9 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-9{width:25% !important;}.fusion-builder-column-9 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-9{width:100% !important;}.fusion-builder-column-9 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-13\" style=\"transform:translate3d(0,0,0);\"><h5>Technicians<\/h5>\n<p>Victoria Luc\u00eda Dold\u00e1n Martelli<\/br>Victoria Freitas Durks<\/br>Ver\u00f3nica Repull\u00e9s Mart\u00edn<\/br>Paloma Campos Ba\u00f1egil<\/br>Nuria Roig S\u00e1nchez<\/br>M\u00f3nica Gorbe Moya<\/br>Mar\u00eda Rodrigo Faus<\/br>M\u00aa Pilar Natividad L\u00f3pez<\/br>M\u00aa Carmen Mart\u00ednez L\u00f3pez<\/br>Laura Olivares Ord\u00f3\u00f1ez<\/br>Laura Gonz\u00e1lez Castillo<\/br>Jos\u00e9 Francisco Gonz\u00e1lez Mu\u00f1oz<\/br>Ignacio Casta\u00f1o L\u00f3pez<\/br>Guillermo Moret Peir\u00f3<\/br>Daniel Gonz\u00e1lez Camblor<\/br>Cristina Mongort Sanchis<\/br>Carme Mar\u00eda Ortega Albiach<\/br>Brenda Palomar de Lucas<\/br>Bea L\u00f3pez Montero<\/br>Arantxa S\u00e1nchez Cosmo<\/br>Andreea Ghiuro<\/br>Andrea Pascual Herrero<\/br>Ana Vercher Grau<\/br>Alejandro Asturiano P\u00e9rez-Chao<\/br>Alba Viala Monle\u00f3n<\/br>Aitana Bolea Cortina<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-10{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-10 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-10{width:25% !important;}.fusion-builder-column-10 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-10{width:100% !important;}.fusion-builder-column-10 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-14\" style=\"transform:translate3d(0,0,0);\"><h5>Administrative assistant<\/h5>\n<p>Paranee Archavarat Sianmekan<\/br>Laura Boix Bartual<\/br>Enrique Castell\u00f3 Moreno<\/br>Carla Gil Ferri<\/br>Roberto San Leandro Garc\u00eda<\/br>Lorena Saz Lluch<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-11{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-11 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-11{width:25% !important;}.fusion-builder-column-11 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-11{width:100% !important;}.fusion-builder-column-11 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 0px;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-15\" style=\"transform:translate3d(0,0,0);\"><h5>Publications<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-1 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-1 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-1 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav,.fusion-tabs.fusion-tabs-1 .nav-tabs,.fusion-tabs.fusion-tabs-1 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-97b43551462481e9612\" aria-selected=\"true\" id=\"fusion-tab-2024\" href=\"#tab-97b43551462481e9612\"><h4 class=\"fusion-tab-heading\">2024<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-6609cc4b67af2d08311\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2023\" href=\"#tab-6609cc4b67af2d08311\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-0ffadcc59afbc018b45\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2022\" href=\"#tab-0ffadcc59afbc018b45\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-752522ae5177bef6cb6\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2021\" href=\"#tab-752522ae5177bef6cb6\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-97b43551462481e9612\" aria-selected=\"true\" id=\"mobile-fusion-tab-2024\" href=\"#tab-97b43551462481e9612\"><h4 class=\"fusion-tab-heading\">2024<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2024\" id=\"tab-97b43551462481e9612\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, Gonzalez-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson A, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marme F, Marth C, McCluggage W, McNeish I, Morice P, Nicum S, Oaknin A, Perez-Fidalgo J, Pignata S, Ramirez P, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan D, Taskiran C, van Driel W, Vergote I, Planchamp F, Sessa C, Fagotti A. Annals of Oncology. 2024 Mar;35(3):248-266. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2023.11.015' target='_blank'>10.1016\/j.annonc.2023.11.015<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38307807' target='_blank'>38307807<\/a><\/p>\n<p>Gastric metaplasia as a precursor of nonconventional dysplasia in inflammatory bowel disease. Musulen E, Gene M, Cuatrecasas M, Amat I, Veiga J, Fernandez-Acenero M, Chimisana V, Tarragona J, Jurado I, Fernandez-Victoria R, Martinez-Ciarpaglini C, Alenda Gonzalez C, Zac C, Fernandez-Figueras M, Esteller M. Human Pathology. 2024 Jan:143:50-61. doi: <a href='https:\/\/doi.org\/10.1016\/j.humpath.2023.11.011' target='_blank'>10.1016\/j.humpath.2023.11.011<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38000679' target='_blank'>38000679<\/a><\/p>\n<p>Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial. Michels S, Massuti B, Vasyliv I, Stratmann J, Frank J, Adams A, Felip E, Grohe C, Rodriguez-Abreu D, Bischoff H, Carcereny I Costa E, Corral J, Pereira E, Fassunke J, Fischer R, Insa A, Koleczko S, Nogova L, Reck M, Reutter T, Riedel R, Schaufler D, Scheffler M, Weisthoff M, Provencio M, Merkelbach-Bruse S, Hellmich M, Sebastian M, Buttner R, Persigehl T, Rosell R, Wolf J. ESMO Open. 2024 Feb 12;9(2):102237. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2024.102237' target='_blank'>10.1016\/j.esmoop.2024.102237<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38350336' target='_blank'>38350336<\/a><\/p>\n<p>Paclitaxel alters melanogenesis and causes pigmentation in the skin of gynecological cancer patients. Montero P, Sanz C, Perez-Fidalgo J, Perez-Leal M, Milara J, Cortijo J. Fundamental &#038; Clinical Pharmacology. 2024 Feb;38(1):183-191. doi: <a href='https:\/\/doi.org\/10.1111\/fcp.12943' target='_blank'>10.1111\/fcp.12943<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37483143' target='_blank'>37483143<\/a><\/p>\n<p>Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for <i>BRCA<\/i> wild-type, platinum-sensitive, recurrent ovarian cancer. Mutch D, Voulgari A, Chen X, Bradley W, Oaknin A, Fidalgo J, Montosa F, Herraez A, Holloway R, Powell M, Nowicka M, Schaefer G, Merchant M, Yan Y. Cancer. 2024 Jan 30. doi: <a href='https:\/\/doi.org\/10.1002\/cncr.35222' target='_blank'>10.1002\/cncr.35222<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38288862' target='_blank'>38288862<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7384-1 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7384-1 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7384-1.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7384-1 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7384-1 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7384-1 .panel-title a:hover, #accordion-7384-1 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7384-1 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7384-1 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7384-1\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"2a718391f09b24031\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7384-1\" data-target=\"#2a718391f09b24031\" href=\"#2a718391f09b24031\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2024<\/span><\/a><\/h4><\/div><div id=\"2a718391f09b24031\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nTargeting HER2-mutant metastatic cervical cancer with neratinib: final results from the phase 2 SUMMIT basket trial. Friedman C, D&#8217;Souza A, Bello Roufai D, Tinker A, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko M, Oaknin A, Spanggaard I, Shapiro G, ElNaggar A, Panni S, Ravichandran V, Frazier A, DiPrimeo D, Eli L, Solit D. Gynecologic Oncology. 2024 Jan 10:181:162-169. doi: <a href='https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.004' target='_blank'>10.1016\/j.ygyno.2023.12.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38211393' target='_blank'>38211393<\/a><\/p>\n<p>The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Pan X, AbdulJabbar K, Coelho-Lima J, Grapa A, Zhang H, Cheung A, Baena J, Karasaki T, Wilson C, Sereno M, Veeriah S, Aitken S, Hackshaw A, Nicholson A, Jamal-Hanjani M, Swanton C, Yuan Y, Le Quesne J, Moore D. Nature Cancer. 2024 Jan 10. doi: <a href='https:\/\/doi.org\/10.1038\/s43018-023-00694-w' target='_blank'>10.1038\/s43018-023-00694-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38200244' target='_blank'>38200244<\/a><\/p>\n<p>The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review. Ciardiello D, Mauri G, Sartore-Bianchi A, Siena S, Zampino M, Fazio N, Cervantes A. Cancer Treatment Reviews. 2024 Jan 12:124:102683. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2024.102683' target='_blank'>10.1016\/j.ctrv.2024.102683<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38237253' target='_blank'>38237253<\/a><\/p>\n<p>The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Caswell D, Gui P, Mayekar M, Law E, Pich O, Bailey C, Boumelha J, Kerr D, Blakely C, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, Angelova M, Gini B, Tamaki W, Allegakoen P, Wu W, Humpton T, Hill W, Tomaschko M, Lu W, Haderk F, Al Bakir M, Nagano A, Gimeno-Valiente F, de Carne Trecesson S, Vendramin R, Barbe V, Mugabo M, Weeden C, Rowan A, McCoach C, Almeida B, Green M, Gomez C, Nanjo S, Barbosa D, Moore C, Przewrocka J, Black J, Gronroos E, Suarez-Bonnet A, Priestnall S, Zverev C, Lighterness S, Cormack J, Olivas V, Cech L, Andrews T, Rule B, Jiao Y, Zhang X, Ashford P, Durfee C, Venkatesan S, Temiz N, Tan L, Larson L, Argyris P, Brown W, Yu E, Rotow J, Guha U, Roper N, Yu J, Vogel R, Thomas N, Marra A, Selenica P, Yu H, Bakhoum S, Chew S, Reis-Filho J, Jamal-Hanjani M, Vousden K, McGranahan N, Van Allen E, Kanu N, Harris R, Downward J, Bivona T, Swanton C. Nature Genetics. 2024 Jan;56(1):60-73. doi: <a href='https:\/\/doi.org\/10.1038\/s41588-023-01592-8' target='_blank'>10.1038\/s41588-023-01592-8<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38049664' target='_blank'>38049664<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-6609cc4b67af2d08311\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2023\" href=\"#tab-6609cc4b67af2d08311\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2023\" id=\"tab-6609cc4b67af2d08311\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nA Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Isla D, Felip E, Garrido P, Insa A, Majem M, Remon J, Trigo JM, de Castro J. Clinical &#038; Translational Oncology. 2023 Jan;25(1):283-291. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02941-5' target='_blank'>10.1007\/s12094-022-02941-5<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36168085' target='_blank'>36168085<\/a><\/p>\n<p>A Phase I\/II Trial of Oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, Kristeleit R, Sarker D, Arkenau T, Roxburgh P, Walter H, Blagden S, Anthoney A, Klencke B, Kowalski M, Banerji U. Clinical Cancer Research. 2023 Jan 17;29(2):331-340. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2074' target='_blank'>10.1158\/1078-0432.CCR-22-2074<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36378548' target='_blank'>36378548<\/a><\/p>\n<p>Alterations in p53, microsatellite stability and lack of MUC5AC expression as molecular features of colorectal carcinoma associated with inflammatory bowel disease. Gene M, Cuatrecasas M, Amat I, Veiga J, Acenero M, Chimisana V, Tarragona J, Jurado I, Fernandez-Victoria R, Ciarpaglini C, Gonzalez C, Zac C, de la Obra P, Fernandez-Figueras M, Esteller M, Musulen E. International Journal of Molecular Sciences. 2023 May 12;24(10):8655. doi: <a href='https:\/\/doi.org\/10.3390\/ijms24108655' target='_blank'>10.3390\/ijms24108655<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37240002' target='_blank'>37240002<\/a><\/p>\n<p>An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Chandarlapaty S, Dickler M, Perez Fidalgo J, Villanueva-Vazquez R, Giltnane J, Gates M, Chang C, Cheeti S, Fredrickson J, Wang X, Collier A, Moore H, Metcalfe C, Lauchle J, Humke E, Bardia A. Clinical Cancer Research. 2023 Aug 1;29(15):2781-2790. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0011' target='_blank'>10.1158\/1078-0432.CCR-23-0011<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37261814' target='_blank'>37261814<\/a><\/p>\n<p>Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors a Phase 1a\/1b nonrandomized controlled trial. Kim T, Bedard P, Lorusso P, Gordon M, Bendell J, Oh D, Ahn M, Garralda E, D&#8217;Angelo S, Desai J, Hodi F, Wainberg Z, Delord J, Cassier P, Cervantes A, Gil-Martin M, Wu B, Patil N, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho B. JAMA Oncology. 2023 Sep 28:e233867. doi: <a href='https:\/\/doi.org\/10.1001\/jamaoncol.2023.3867' target='_blank'>10.1001\/jamaoncol.2023.3867<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37768658' target='_blank'>37768658<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7384-2 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7384-2 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7384-2.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7384-2 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7384-2 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7384-2 .panel-title a:hover, #accordion-7384-2 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7384-2 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7384-2 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7384-2\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"01c0a36d205f0d67b\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7384-2\" data-target=\"#01c0a36d205f0d67b\" href=\"#01c0a36d205f0d67b\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2023<\/span><\/a><\/h4><\/div><div id=\"01c0a36d205f0d67b\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nClinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601. Perez-Fidalgo JA, Guerra E, Garcia Y, Iglesias M, Hernandez-Sosa M, Estevez-Garcia P, Manso Sanchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, Gonzalez-Martin A. International Journal of Gynecological Cancer. 2023 Jun 5;33(6):929-936. doi: <a href='https:\/\/doi.org\/10.1136\/ijgc-2022-004028' target='_blank'>10.1136\/ijgc-2022-004028<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36759001' target='_blank'>36759001<\/a><\/p>\n<p>Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. Redondo A, Barretina P, P\u00e9rez-Fidalgo A, Rubio MJ, Gonz\u00e1lez-Mart\u00edn A. Journal of Gynecologic Oncology. 2023 Sep;34(5):e57. doi: <a href='https:\/\/doi.org\/10.3802\/jgo.2023.34.e57' target='_blank'>10.3802\/jgo.2023.34.e57<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37116953' target='_blank'>37116953<\/a><\/p>\n<p>Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. Escudero Vilaplana V, Collado Borrell R, De Castro J, Insa A, Martinez A, Fernandez E, Sullivan I, Flores A, Arrabal N, Carcedo D, Manzaneque A. Journal of Medical Economics. 2023 Jan-Dec;26(1):445-453. doi: <a href='https:\/\/doi.org\/10.1080\/13696998.2023.2188844' target='_blank'>10.1080\/13696998.2023.2188844<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36883193' target='_blank'>36883193<\/a><\/p>\n<p>Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology+MIR section. Martinez D, Quilez-Cutillas A, Jimenez-Labaig P, Sesma A, Tarazona N, Pacheco-Barcia V, Obispo B, Paez D, Quintanar T, Sanchez-Canovas M, Montes A, Felip E, Rodriguez-Lescure A, Elez E. Clinical &#038; translational oncology. 2023 Mar;25(3):796-802. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02989-3' target='_blank'>10.1007\/s12094-022-02989-3<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36418642' target='_blank'>36418642<\/a><\/p>\n<p>Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Kroese T, van Laarhoven H, Schoppman S, Deseyne P, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen H, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns C, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, Cellini F, D&#8217;Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen M, Hulshof M, van Dieren J, Vollebergh M, van Sandick J, Jeene P, Muijs C, Slingerland M, Voncken F, Hartgrink H, Creemers G, van der Sangen M, Nieuwenhuijzen G, Berbee M, Verheij M, Wijnhoven B, Beerepoot L, Mohammad N, Mook S, Ruurda J, Kolodziejczyk P, Polkowski W, Wyrwicz L, Alsina M, Pera M, Kanonnikoff T, Cervantes A, Nilsson M, Monig S, Wagner A, Guckenberger M, Griffiths E, Smyth E, Hanna G, Markar S, Chaudry M, Hawkins M, Cheong E, van Hillegersberg R, van Rossum P. European Journal of Cancer. 2023 Feb 24;185:28-39. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejca.2023.02.015' target='_blank'>10.1016\/j.ejca.2023.02.015<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36947929' target='_blank'>36947929<\/a><\/p>\n<p>Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score. Marti-Aguado D, Arnouk J, Liang J, Lara-Romero C, Behari J, Furlan A, Jimenez-Pastor A, Ten-Esteve A, Alfaro-Cervello C, Bauza M, Gallen-Peris A, Gimeno-Torres M, Merino-Murgui V, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferr\u00e1ndez-Izquierdo A, Aguilera V, Giesteira B, Fran\u00e7a M, Monton C, Escudero-Garc\u00eda D, Alberich-Bayarri A, Serra M, Bataller R, Romero-Gomez M, Marti-Bonmati L. Liver International. 2023 Oct 30. doi: <a href='https:\/\/doi.org\/10.1111\/liv.15766' target='_blank'>10.1111\/liv.15766<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37904633' target='_blank'>37904633<\/a><\/p>\n<p>Diagnostic algorithm to subclassify atypical spitzoid tumors in low and high risk according to their methylation status. Gonz\u00e1lez-Mu\u00f1oz J, S\u00e1nchez-Sendra B, Monteagudo C. International Journal of Molecular Sciences. 2023 Dec 25;25(1):318. doi: <a href='https:\/\/doi.org\/10.3390\/ijms25010318' target='_blank'>10.3390\/ijms25010318<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38203489' target='_blank'>38203489<\/a><\/p>\n<p>Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Nature Medicine. 2023 Dec 5. doi: <a href='https:\/\/doi.org\/10.1038\/s41591-023-02696-8' target='_blank'>10.1038\/s41591-023-02696-8<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38052910' target='_blank'>38052910<\/a><\/p>\n<p>Does month of birth influence colorectal cancer prognosis?. Mart\u00edn-Ar\u00e9valo J, Moro-Valdezate D, Pla-Mart\u00ed V, Garc\u00eda-Botello S, Moya-Marcos P, Izquierdo-Moreno A, P\u00e9rez-Santiago L, Casado-Rodrigo D, Rosello-Ker\u00e4nen S, Esp\u00ed-Mac\u00edas A. Langenbecks Archives of Surgery. 2023 Oct 26;408(1):419. doi: <a href='https:\/\/doi.org\/10.1007\/s00423-023-03161-3' target='_blank'>10.1007\/s00423-023-03161-3<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37882968' target='_blank'>37882968<\/a><\/p>\n<p>Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. De Castro J, Insa A, Collado-Borrell R, Escudero-Vilaplana V, Martinez A, Fernandez E, Sullivan I, Arrabal N, Carcedo D, Manzaneque A. BMC Pulmonary Medicine. 2023 Feb 21;23(1):69. doi: <a href='https:\/\/doi.org\/10.1186\/s12890-023-02356-0' target='_blank'>10.1186\/s12890-023-02356-0<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36809990' target='_blank'>36809990<\/a><\/p>\n<p>Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Ciardiello F, Bang Y, Cervantes A, Dvorkin M, Lopez C, Metges J, Ruiz A, Calvo M, Strickland A, Kannourakis G, Muro K, Kawakami H, Wei J, Borg C, Zhu Z, Gupta N, Pelham R, Shen L. Cancer Medicine. 2023 Jun;12(12):13145-13154. doi: <a href='https:\/\/doi.org\/10.1002\/cam4.5997' target='_blank'>10.1002\/cam4.5997<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37260158' target='_blank'>37260158<\/a><\/p>\n<p>Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon D, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y. Lancet Oncology. 2023 Aug;24(8):925-935. doi: <a href='https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9' target='_blank'>10.1016\/S1470-2045(23)00275-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37541273' target='_blank'>37541273<\/a><\/p>\n<p>European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer. Martinelli E, Arnold D, Cervantes A, Stintzing S, Van Cutsem E, Tabernero J, Taieb J, Wasan H, Ciardiello F. Cancer Treatment Reviews. 2023 Apr;115:102541. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102541' target='_blank'>10.1016\/j.ctrv.2023.102541<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36931147' target='_blank'>36931147<\/a><\/p>\n<p>Evaluation of results after 112 radioembolizations with 90Y-microspheres. Casans-Tormo I, Guijarro-Rosaleny J, Lluch-Garcia P, Rodriguez-Parra H, Rosello-Keranen S, Asensio-Valero L. Revista Espanola de Medicina Nuclear e Imagen Molecular. 2023 Jul-Aug;42(4):255-264. doi: <a href='https:\/\/doi.org\/10.1016\/j.remnie.2023.05.004' target='_blank'>10.1016\/j.remnie.2023.05.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37269983' target='_blank'>37269983<\/a><\/p>\n<p>First-Line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Zhou C, Solomon B, Loong H, Park K, Perol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak M, Santini F, Elamin Y, Drilon A, Wolf J, Payakachat N, Uh M, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin A, Lin B, Goto K. New England Journal of Medicine. 2023 Nov 16;389(20):1839-1850. doi: <a href='https:\/\/doi.org\/10.1056\/NEJMoa2309457' target='_blank'>10.1056\/NEJMoa2309457<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37870973' target='_blank'>37870973<\/a><\/p>\n<p>FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer. Cervantes A, Prager GW. ESMO Open. 2023 Feb 20;8(2):100883. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.100883' target='_blank'>10.1016\/j.esmoop.2023.100883<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36812740' target='_blank'>36812740<\/a><\/p>\n<p>Hern\u00e1ndez J,Chow CY,Chatras H,Fran\u00e7a PDD,Samuels ZV,Cornejo M,King GF,Lewis JS,Reiner T,Gonzales J. Development and Validation of Nerve-Targeted Bacteriochlorin Sensors. J. Am. Chem. Soc. 2023. 145. (26):p. 14276-14287. IF:14,400. (1). <\/p>\n<p>How organoids can improve personalized treatment in patients with gastro-esophageal tumors. Cabeza-Segura M, Garcia-Mic\u00f2 B, La Noce M, Nicoletti GF, Conti V, Filippelli A, Fleitas T, Cervantes A, Castillo J, Papaccio F. Current Opinion in Pharmacology. 2023 Feb 23;69:102348. doi: <a href='https:\/\/doi.org\/10.1016\/j.coph.2023.102348' target='_blank'>10.1016\/j.coph.2023.102348<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36842387' target='_blank'>36842387<\/a><\/p>\n<p>In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100763' target='_blank'>10.1016\/j.esmoop.2022.100763<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36603523' target='_blank'>36603523<\/a><\/p>\n<p>In the literature: July 2023. Gambardella V, Gimeno-Valiente F, Rosell\u00f3 S, Cervantes A. ESMO Open. 2023 Aug;8(4):101612. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101612' target='_blank'>10.1016\/j.esmoop.2023.101612<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37467659' target='_blank'>37467659<\/a><\/p>\n<p>In the Literature: March 2023. Gambardella V, Tarazona N, Roda D, Cervantes A. ESMO Open. 2023 Apr;8(2):101203. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101203' target='_blank'>10.1016\/j.esmoop.2023.101203<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37018871' target='_blank'>37018871<\/a><\/p>\n<p>In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101562' target='_blank'>10.1016\/j.esmoop.2023.101562<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37196398' target='_blank'>37196398<\/a><\/p>\n<p>In the literature: September 2023. Lamarca A, Moreno V, Gambardella V, Cervantes A. ESMO Open. 2023 Oct 16;8(6):102032. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.102032' target='_blank'>10.1016\/j.esmoop.2023.102032<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37852035' target='_blank'>37852035<\/a><\/p>\n<p>Lenvatinib plus pembrolizumab a new effective combination of targeted agents. Perez-Fidalgo J, Martinelli E. ESMO Open. 2023 Feb 28;8(2):101157. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101157' target='_blank'>10.1016\/j.esmoop.2023.101157<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36863093' target='_blank'>36863093<\/a><\/p>\n<p>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Journal of Clinical Oncology. 2023 Nov 20;41(33):5080-5089. doi: <a href='https:\/\/doi.org\/10.1200\/JCO.22.02773' target='_blank'>10.1200\/JCO.22.02773<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37967516' target='_blank'>37967516<\/a><\/p>\n<p>Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery &#8211; a five-year follow-up of the RAPIDO Trial. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund A, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B. Annals of Surgery. 2023 Oct 1;278(4):e766-e772. doi: <a href='https:\/\/doi.org\/10.1097\/SLA.0000000000005799' target='_blank'>10.1097\/SLA.0000000000005799<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36661037' target='_blank'>36661037<\/a><\/p>\n<p>Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Mendez A, Manero-Ruperez N, Re DL, Rivas EI, Guiu M, Zwick M, Iglesias M, Martinez-Ciarpaglini C, Tarazona N, Varese M, Hernando-Momblona X, Canellas-Socias A, Orrillo M, Garrido M, Saoudi N, Elez E, Navarro P, Tabernero J, Gomis RR, Batlle E, Pisonero J, Cervantes A, Montagut C, Calon A. Nature Communications. 2023 Feb 10;14(1):746. doi: <a href='https:\/\/doi.org\/10.1038\/s41467-023-36334-1' target='_blank'>10.1038\/s41467-023-36334-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36765091' target='_blank'>36765091<\/a><\/p>\n<p>Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003' target='_blank'>10.1016\/j.annonc.2022.10.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36307056' target='_blank'>36307056<\/a><\/p>\n<p>Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C Study. Shah M, Yoshino T, Tebbutt N, Grothey A, Tabernero J, Xu R, Cervantes A, Oh S, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu V, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Taieb J, Van Cutsem E. Clinical Colorectal Cancer. 2022 Nov 11:S1533-0028(22)00125-6. doi: <a href='https:\/\/doi.org\/10.1016\/j.clcc.2022.11.002' target='_blank'>10.1016\/j.clcc.2022.11.002<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36503738' target='_blank'>36503738<\/a><\/p>\n<p>Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Jhaveri K, Eli L, Wildiers H, Hurvitz S, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang E, Spanggaard I, Reid S, Burkard M, Vinayak S, Prat A, Arnedos M, Bidard F, Loi S, Crown J, Bhave M, Piha-Paul S, Suga J, Chia S, Saura C, Garcia-Saenz J, Gambardella V, de Miguel M, Gal-Yam E, Rapael A, Stemmer S, Ma C, Hanker A, Ye D, Goldman J, Bose R, Peterson L, Bell J, Frazier A, DiPrimeo D, Wong A, Arteaga C, Solit D. Annals of Oncology. 2023 Oct;34(10):885-898. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2023.08.003' target='_blank'>10.1016\/j.annonc.2023.08.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37597578' target='_blank'>37597578<\/a><\/p>\n<p>Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Vergote I, Perez-Fidalgo J, Hamilton E, Valabrega G, Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson D, Guerra E, Scambia G, Henry S, Wimberger P, Miller D, Klat J, Martinez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Hogdall E, Farinas-Madrid L, Monk B, Michel D, Kauffman M, Shacham S, Mirza M, Makker V. Journal of Clinical Oncology. 2023 Dec 10;41(35):5400-5410. doi: <a href='https:\/\/doi.org\/10.1200\/JCO.22.02906' target='_blank'>10.1200\/JCO.22.02906<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37669480' target='_blank'>37669480<\/a><\/p>\n<p>Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. British Journal of Cancer. 2023 Sep;129(5):797-810. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-023-02349-0' target='_blank'>10.1038\/s41416-023-02349-0<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37474720' target='_blank'>37474720<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101558' target='_blank'>10.1016\/j.esmoop.2023.101558<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37236086' target='_blank'>37236086<\/a><\/p>\n<p>Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. Provencio M, Nadal E, Gonzalez-Larriba J, Martinez-Marti A, Bernabe R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, Lopez Vivanco G, Camps C, Lopez-Castro R, Moran T, Barneto I, Rodriguez-Abreu D, Serna-Blasco R, Benitez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martin-Lopez J, Cruz-Bermudez A, Massuti B, Romero A. New England Journal of Medicine. 2023 Aug 10;389(6):504-513. doi: <a href='https:\/\/doi.org\/10.1056\/NEJMoa2215530' target='_blank'>10.1056\/NEJMoa2215530<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37379158' target='_blank'>37379158<\/a><\/p>\n<p>Pharmacokinetics (PK) of Tiragolumab in first-in-human study in patients with mixed solid tumors (GO30103). Garralda E, Oh D, Italiano A, Bedard P, Delord J, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh C, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho B, Kim T, Wu B. Journal of Clinical Pharmacology. 2023 Dec 17. doi: <a href='https:\/\/doi.org\/10.1002\/jcph.2397' target='_blank'>10.1002\/jcph.2397<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38105505' target='_blank'>38105505<\/a><\/p>\n<p>Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Carneiro B, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma W, Coveler A, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weiskittel T, Li H, Borden B, Harvey R, Sahebjam S, Cervantes A, Koukol A, Mazar A, Steeghs N, Kurzrock R, Giles F, Munster P. Clinical Cancer Research. 2023 Nov 20. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1916' target='_blank'>10.1158\/1078-0432.CCR-23-1916<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37982822' target='_blank'>37982822<\/a><\/p>\n<p>Phase Ia\/b Study of giredestrant \u00b1palbociclib and \u00b1luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer. Jhaveri KL, Bellet-Ezquerra M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-V\u00e1zquez R, Kabos P, Garc\u00eda Est\u00e9vez L, Lopez-Miranda E, Perez Fidalgo JA, Perez-Garcia JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Clinical Cancer Research. 2023 Nov 3. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1796' target='_blank'>10.1158\/1078-0432.CCR-23-1796<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37921755' target='_blank'>37921755<\/a><\/p>\n<p>Preoperative treatment of locally advanced rectal cancer. Sebag-Montefiore D, Cervantes A, Rodel C. New England Journal of Medicine. 2023 Oct 26;389(17):1631. doi: <a href='https:\/\/doi.org\/10.1056\/NEJMc2309857' target='_blank'>10.1056\/NEJMc2309857<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37888929' target='_blank'>37888929<\/a><\/p>\n<p>Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Papaccio F, Garcia-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutierrez-Bravo MF, Alfaro-Cervello C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zuniga-Trejos S, Carbonell-Asins JA, Fleitas T, Rosello S, Huerta M, Sanchez Del Pino MM, Sabater L, Roda D, Tarazona N, Cervantes A, Castillo J. Journal of Experimental &#038; Clinical Cancer Research. 2023 Jan 6;42(1):8. doi: <a href='https:\/\/doi.org\/10.1186\/s13046-022-02591-z' target='_blank'>10.1186\/s13046-022-02591-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36604765' target='_blank'>36604765<\/a><\/p>\n<p>Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Spahn J, Li S, Cha E, Riely G, Gettinger S. ESMO Open. 2023 Mar 3;8(2):101160. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101160' target='_blank'>10.1016\/j.esmoop.2023.101160<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36871392' target='_blank'>36871392<\/a><\/p>\n<p>SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023). Garcia-Campelo R, Sullivan I, Arriola E, Insa A, Vidal O, Cruz-Castellanos P, Moran T, Reguart N, Zugazagoitia J, Domine M. Clinical &#038; Translational Oncology. 2023 Sep;25(9):2760-2762. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-023-03290-7' target='_blank'>10.1007\/s12094-023-03290-7<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37556098' target='_blank'>37556098<\/a><\/p>\n<p>SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Garcia-Campelo R, Sullivan I, Arriola E, Insa A, Juan Vidal O, Cruz-Castellanos P, Moran T, Reguart N, Zugazagoitia J, Domine M. Clinical &#038; Translational Oncology. 2023 Sep;25(9):2679-2691. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-023-03216-3' target='_blank'>10.1007\/s12094-023-03216-3<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37418123' target='_blank'>37418123<\/a><\/p>\n<p>Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. Gimeno-Valiente F, Mart\u00edn-Arana J, T\u00e9bar-Mart\u00ednez R, Gambardella V, Mart\u00ednez-Ciarpaglini C, Garc\u00eda-Mic\u00f3 B, Mart\u00ednez-Castedo B, Palomar B, Garc\u00eda-Bartolom\u00e9 M, Segu\u00ed V, Huerta M, Moro-Valdezate D, Pla-Mart\u00ed V, P\u00e9rez-Santiago L, Rosell\u00f3 S, Roda D, Cervantes A, Tarazona N. ESMO Open. 2023 Nov 9;8(6):102051. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.102051' target='_blank'>10.1016\/j.esmoop.2023.102051<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37951129' target='_blank'>37951129<\/a><\/p>\n<p>Strategies for improving detection of circulating tumor DNA using next generation sequencing. Roberto T, Jorge M, Francisco G, Noelia T, Pilar R, Andres C. Cancer Treatment Reviews. 2023 Sep;119:102595. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102595' target='_blank'>10.1016\/j.ctrv.2023.102595<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37390697' target='_blank'>37390697<\/a><\/p>\n<p>Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D&#8217;Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R. European Journal of Surgical Oncology. 2023 Jan;49(1):21-28. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejso.2022.09.012' target='_blank'>10.1016\/j.ejso.2022.09.012<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36184420' target='_blank'>36184420<\/a><\/p>\n<p>The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Thorell K, Munoz-Ramirez Z, Wang D, Sandoval-Motta S, Boscolo Agostini R, Ghirotto S, Torres R, Falush D, Camargo M, Rabkin C. Nature Communications. 2023 Dec 11;14(1):8184. doi: <a href='https:\/\/doi.org\/10.1038\/s41467-023-43562-y' target='_blank'>10.1038\/s41467-023-43562-y<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38081806' target='_blank'>38081806<\/a><\/p>\n<p>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO\/World Congress on Gastrointestinal Cancer, Barcelona, 2022. Ducreux M, Abou-Alfa G, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet J, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O&#8217;Connor J, O&#8217;Reilly E, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. ESMO Open. 2023 May 30;8(3):101567. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101567' target='_blank'>10.1016\/j.esmoop.2023.101567<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37263081' target='_blank'>37263081<\/a><\/p>\n<p>The percentage of mesorectal infiltration as a prognostic factor after curative surgery for pT3 rectal cancer. Sancho-Muriel J, Giner F, Cholewa H, Garcia-Granero A, Rosell\u00f3 S, Flor-Lorente B, Cervantes A, Garcia-Granero E, Frasson M. Colorectal Disease. 2023 Jun;25(6):1135-1143. doi: <a href='https:\/\/doi.org\/10.1111\/codi.16522' target='_blank'>10.1111\/codi.16522<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36790134' target='_blank'>36790134<\/a><\/p>\n<p>The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice. Badia-Ramentol J, Gimeno-Valiente F, Dur\u00e9ndez E, Mart\u00ednez-Ciarpaglini C, Linares J, Iglesias M, Cervantes A, Calon A, Tarazona N. Cancer Treatment Reviews. 2023 Dec:121:102643. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102643' target='_blank'>10.1016\/j.ctrv.2023.102643<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37871463' target='_blank'>37871463<\/a><\/p>\n<p>The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. Dijkstra E, Zwart W, Nilsson P, Putter H, Roodvoets A, Meershoek-Klein Kranenbarg E, Frodin J, Nygren P, Ostergaard L, Kersten C, Verbiene I, Cervantes A, Hendriks M, Capdevila J, Edhemovic I, van de Velde C, Marijnen C, van Etten B, Hospers G, Glimelius B. ESMO Open. 2023 Mar 3;8(2):101158. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101158' target='_blank'>10.1016\/j.esmoop.2023.101158<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36871393' target='_blank'>36871393<\/a><\/p>\n<p>Timing of meals and sleep in the Mediterranean population: the effect of taste, genetics, environmental determinants, and interactions on obesity phenotypes. Barragan R, Fernandez Carrion R, Asensio Marquez EM, Ortega Azorin C, Alvarez Sala A, Perez-Fidalgo A, Sorli JV, Portoles O, Gonzalez Monje I, St-Onge MP, Corella D. Nutrients. 2023 Jan 30;15(3):708. doi: <a href='https:\/\/doi.org\/10.3390\/nu15030708' target='_blank'>10.3390\/nu15030708<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36771415' target='_blank'>36771415<\/a><\/p>\n<p>Trisomy 12p mosaicism syndrome in a patient with hypopigmented cutaneous mosaicism and three cell lines in peripheral blood. Porcar Saura S, Diaz Gimenez M, Guillen-Climent S, Villar C, Ruiz Quilez A, Abellan Sanchez M, Cuesta Peredo A, Martin J. Journal of the European Academy of Dermatology and Venereology. 2023 Jan;37(1):e54-e58. doi: <a href='https:\/\/doi.org\/10.1111\/jdv.18555' target='_blank'>10.1111\/jdv.18555<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35993792' target='_blank'>35993792<\/a><\/p>\n<p>Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Cervantes A, Martinelli E. Annals of Oncology. 2023 Nov 7:S0923-7534(23)04335-1. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2023.10.129' target='_blank'>10.1016\/j.annonc.2023.10.129<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37951473' target='_blank'>37951473<\/a><\/p>\n<p>Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Perez-Fidalgo J, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Verdum J, de Alava E, Lopez M, Marquina G, Sebio A. Therapeutic Advances in Medical Oncology. 2023 Mar 28;15:17588359231157645. doi: <a href='https:\/\/doi.org\/10.1177\/17588359231157645' target='_blank'>10.1177\/17588359231157645<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37007636' target='_blank'>37007636<\/a><\/p>\n<p>Ximenez E, Ruiperez A. Selective neoadjuvant therapy in locally advanced rectal cancer: Who and why?. Cirugia Espanola. 2023 May;101(5):309-311. doi: <a href='https:\/\/doi.org\/10.1016\/j.cireng.2022.11.007' target='_blank'>10.1016\/j.cireng.2022.11.007<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36423876' target='_blank'>36423876<\/a><\/p>\n<p>Young oncologists&#8217; perspective on the role and future of the clinician-scientist in oncology. Lim K, Westphalen C, Berghoff A, Cardone C, Connolly E, Guven D, Kfoury M, Kocakavuk E, Mando P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sanchez-Bayona R, Sobczuk P, Starzer A, Tecic Vuger A, Zhu H, Cruz-Ordinario M, Altuna S, Canario R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T. Esmo Open. 2023 Aug 31;8(5):101625. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101625' target='_blank'>10.1016\/j.esmoop.2023.101625<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37659290' target='_blank'>37659290<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-0ffadcc59afbc018b45\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2022\" href=\"#tab-0ffadcc59afbc018b45\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2022\" id=\"tab-0ffadcc59afbc018b45\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nA fast-growing tumor on the head of an elderly woman: answer. Benavent M, Delgado V, Adrian J, Felix F, Ciarpaglini C. American Journal of Dermatopathology. 2022 Jul 1;44(7):535-536. doi: <a href='https:\/\/doi.org\/10.1097\/DAD.0000000000002153' target='_blank'>10.1097\/DAD.0000000000002153<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35704913' target='_blank'>35704913<\/a><\/p>\n<p>A fast-growing tumor on the head of an elderly woman: challenge. Benavent M, Delgado V, Adrian J, Felix F, Ciarpaglini C. American Journal of Dermatopathology. 2022 Jul 1;44(7):e71-e74. doi: <a href='https:\/\/doi.org\/10.1097\/DAD.0000000000002154' target='_blank'>10.1097\/DAD.0000000000002154<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35704916' target='_blank'>35704916<\/a><\/p>\n<p>A novel adenine-based diruthenium(III) complex: Synthesis, crystal structure, electrochemical properties and evaluation of the anticancer activity. Orts-Arroyo M, Gutierrez F, Gil-Tebar A, Ibarrola-Villava M, Jimenez-Marti E, Silvestre-Llora A, Castro I, Ribas G, Martinez-Lillo J. Journal of Inorganic Biochemistry. 2022 Apr 6;232:111812. doi: <a href='https:\/\/doi.org\/10.1016\/j.jinorgbio.2022.111812' target='_blank'>10.1016\/j.jinorgbio.2022.111812<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35421769' target='_blank'>35421769<\/a><\/p>\n<p>A phase III trial of alpelisib plus trastuzumab +\/- fulvestrant versus trastuzumab plus chemotherapy in HER2+PIK3CA-mutated breast cancer. Perez-Fidalgo J, Criscitiello C, Carrasco E, Regan M, Di Leo A, Ribi K, Adam V, Bedard P. Future Oncology. 2022 Jun;18(19):2339-2349. doi: <a href='https:\/\/doi.org\/10.2217\/fon-2022-0045' target='_blank'>10.2217\/fon-2022-0045<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35465733' target='_blank'>35465733<\/a><\/p>\n<p>A standardized liquid biopsy preanalytical protocol for downstream circulating-free dna applications. Earl J, Calabuig-Farinas S, Sarasquete M, Romay L, Lopez-Tarruella S, Paricio B, Rodriguez M, Leoz K, Porto M, Tarazona N, Losa J, Toledo R. Jove-Journal of Visualized Experiments. 2022 Sep 16;(187). doi: <a href='https:\/\/doi.org\/10.3791\/64123' target='_blank'>10.3791\/64123<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36190291' target='_blank'>36190291<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7384-3 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7384-3 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7384-3.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7384-3 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7384-3 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7384-3 .panel-title a:hover, #accordion-7384-3 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7384-3 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7384-3 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7384-3\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"95864f96e7b3ca0bd\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7384-3\" data-target=\"#95864f96e7b3ca0bd\" href=\"#95864f96e7b3ca0bd\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2022<\/span><\/a><\/h4><\/div><div id=\"95864f96e7b3ca0bd\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nAlternative splicing, epigenetic modifications and cancer: a dangerous triangle, or a hopeful one?. Gimeno-Valiente F, Lopez-Rodas G, Castillo J, Franco L. Cancers. 2022 Jan 22;14(3):560. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14030560' target='_blank'>10.3390\/cancers14030560<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35158828' target='_blank'>35158828<\/a><\/p>\n<p>Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. Marti-Aguado D, Jimenez-Pastor A, Alberich-Bayarri A, Rodriguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrandez A, Aguilera V, Escudero-Garcia D, Serra MA, Marti-Bonmati L. Radiology. 2022 Feb;302(2):345-354. doi: <a href='https:\/\/doi.org\/10.1148\/radiol.2021211027' target='_blank'>10.1148\/radiol.2021211027<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34783592' target='_blank'>34783592<\/a><\/p>\n<p>Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Clinical Cancer Research. 2022 Feb 1;28(3):507-517. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2404' target='_blank'>10.1158\/1078-0432.CCR-21-2404<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34625408' target='_blank'>34625408<\/a><\/p>\n<p>Clinical management of metastatic colorectal cancer in the era of precision medicine. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. CA-A Cancer Journal for Clinicians. 2022 Jul;72(4):372-401. doi: <a href='https:\/\/doi.org\/10.3322\/caac.21728' target='_blank'>10.3322\/caac.21728<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35472088' target='_blank'>35472088<\/a><\/p>\n<p>Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Supportive Care in Cancer. 2022 Feb;30(2):1483-1491. doi: <a href='https:\/\/doi.org\/10.1007\/s00520-021-06513-1' target='_blank'>10.1007\/s00520-021-06513-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34529142' target='_blank'>34529142<\/a><\/p>\n<p>Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy &#8211; results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial. Peters S, Pujol J, Dafni U, Domine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Molla A, Gervais R, Lopez Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, Gonzalez Larriba J, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel R, Le Pechoux C, De Ruysscher D, ETOP\/IFCT 4-12 STIMULI Collaborators. Annals of Oncology. 2022 Jan;33(1):67-79. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.09.011' target='_blank'>10.1016\/j.annonc.2021.09.011<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34562610' target='_blank'>34562610<\/a><\/p>\n<p>Corrigendum to &#8220;Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up&#8221;: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2022 Jun;33(6):666. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.03.009' target='_blank'>10.1016\/j.annonc.2022.03.009<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35365377' target='_blank'>35365377<\/a><\/p>\n<p>Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Kroese T, van Hillegersberg R, Schoppmann S, Deseyne P, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkings M, Smyth E, Markar S, Hanna G, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns C, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D&#8217;Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick J, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot L, Kolodziejczyk P, Polkowski W, Alsina M, Pera M, Kanonnikoff T, Nilsson M, Guckenberger M, Monig S, Wagner D, Wyrwicz L, Berbee M, Gockel I, Lordick F, Griffiths E, Verheij M, van Rossum P, van Laarhoven H, OMEC working group. European Journal of Cancer. 2022 Feb 5;164:18-29. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejca.2021.11.032' target='_blank'>10.1016\/j.ejca.2021.11.032<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35134666' target='_blank'>35134666<\/a><\/p>\n<p>Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA\/ENGOT-OV26\/GOG-3012 study. O&#8217;Cearbhaill R, Perez-Fidalgo J, Monk B, Tusquets I, McCormick C, Fuentes J, Moore R, Vulsteke C, Shahin M, Forget F, Bradley W, Hietanen S, O&#8217;Malley D, Dorum A, Slomovitz B, Baumann K, Selle F, Calvert P, Artioli G, Levy T, Kumar A, Malinowska I, Li Y, Gupta D, Gonzalez-Martin A. Gynecologic Oncology. 2022 Jul;166(1):36-43. doi: <a href='https:\/\/doi.org\/10.1016\/j.ygyno.2022.04.012' target='_blank'>10.1016\/j.ygyno.2022.04.012<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35550709' target='_blank'>35550709<\/a><\/p>\n<p>ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. Annals of Oncology. 2022 Nov;33(11):1119-1133. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1941' target='_blank'>10.1016\/j.annonc.2022.07.1941<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35963481' target='_blank'>35963481<\/a><\/p>\n<p>ESMO recommendations on the use of circulating tumour DNA assays for patients  with cancer: a report from the ESMO Precision Medicine Working Group. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. Annals of Oncology. 2022 Aug;33(8):750-768. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520' target='_blank'>10.1016\/j.annonc.2022.05.520<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35809752' target='_blank'>35809752<\/a><\/p>\n<p>Evaluation of antineoplastic delayed-type hypersensitivity skin reactions in vitro. Roger I, Montero P, Garcia A, Milara J, Ribera P, Perez-Fidalgo JA, Cortijo J. Pharmaceuticals. 2022 Sep 6;15(9):1111. doi: <a href='https:\/\/doi.org\/10.3390\/ph15091111' target='_blank'>10.3390\/ph15091111<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36145332' target='_blank'>36145332<\/a><\/p>\n<p>First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2022 Feb;71(2):417-431. doi: <a href='https:\/\/doi.org\/10.1007\/s00262-021-02973-w' target='_blank'>10.1007\/s00262-021-02973-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34216247' target='_blank'>34216247<\/a><\/p>\n<p>First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. Clinical Cancer Research. 2022 Aug 15;28(16):3452-3463. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4020' target='_blank'>10.1158\/1078-0432.CCR-21-4020<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35699599' target='_blank'>35699599<\/a><\/p>\n<p>First-in-human, open-label, phase 1\/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T&#8217;jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Cancer Chemotherapy and Pharmacology. 2022 Apr;89(4):499-514. doi: <a href='https:\/\/doi.org\/10.1007\/s00280-022-04414-6' target='_blank'>10.1007\/s00280-022-04414-6<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35298698' target='_blank'>35298698<\/a><\/p>\n<p>Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):1005-1020. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004' target='_blank'>10.1016\/j.annonc.2022.07.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35914639' target='_blank'>35914639<\/a><\/p>\n<p>Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: <a href='https:\/\/doi.org\/10.1177\/10732748221131000' target='_blank'>10.1177\/10732748221131000<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36355430' target='_blank'>36355430<\/a><\/p>\n<p>In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100479' target='_blank'>10.1016\/j.esmoop.2022.100479<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35472677' target='_blank'>35472677<\/a><\/p>\n<p>In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100352' target='_blank'>10.1016\/j.esmoop.2021.100352<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34920292' target='_blank'>34920292<\/a><\/p>\n<p>In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100411' target='_blank'>10.1016\/j.esmoop.2022.100411<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35219243' target='_blank'>35219243<\/a><\/p>\n<p>In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100556' target='_blank'>10.1016\/j.esmoop.2022.100556<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35961192' target='_blank'>35961192<\/a><\/p>\n<p>In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100643' target='_blank'>10.1016\/j.esmoop.2022.100643<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36403559' target='_blank'>36403559<\/a><\/p>\n<p>Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-022-02005-z' target='_blank'>10.1038\/s41416-022-02005-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36253523' target='_blank'>36253523<\/a><\/p>\n<p>Minimal residual disease in gastroesophageal adenocarcinoma: thesearch for the invisible. Tarazona N, Gimeno-Valiente F, Cervantes A. ESMO Open. 2022 Aug;7(4):100547. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100547' target='_blank'>10.1016\/j.esmoop.2022.100547<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35849878' target='_blank'>35849878<\/a><\/p>\n<p>MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, Luce A, Cossu A, Vadakekolathu J, Miles A, Boocock D, Robinson A, Schwerdtfeger M, Tirino V, Papaccio F, Caraglia M, Regad T, Desiderio V. Journal of Experimental &#038; Clinical Cancer Research. 2022 Jan 11;41(1):20. doi: <a href='https:\/\/doi.org\/10.1186\/s13046-021-02233-w' target='_blank'>10.1186\/s13046-021-02233-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35016717' target='_blank'>35016717<\/a><\/p>\n<p>Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. Jimenez-Marti E, Hurtado-Genoves G, Aguilar-Ballester M, Martinez-Hervas S, Gonzalez-Navarro H. Nutrients. 2022 Sep 13;14(18):3775. doi: <a href='https:\/\/doi.org\/10.3390\/nu14183775' target='_blank'>10.3390\/nu14183775<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36145148' target='_blank'>36145148<\/a><\/p>\n<p>Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003' target='_blank'>10.1016\/j.annonc.2022.07.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35914638' target='_blank'>35914638<\/a><\/p>\n<p>Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: is it cost-effective in Spain. Moya-Alarcon C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta M, Perez-Fidalgo J, Redondo A. Gynecologic Oncology. 2022 Feb;164(2):406-414. doi: <a href='https:\/\/doi.org\/10.1016\/j.ygyno.2021.11.011' target='_blank'>10.1016\/j.ygyno.2021.11.011<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34844775' target='_blank'>34844775<\/a><\/p>\n<p>Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo MR, Casal Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martin-Lopez J, Garcia-Garcia F, Casarrubios M, Franco F, Sanchez-Herrero E, Massuti B, Cruz-Bermudez A, Romero A. Journal of Clinical Oncology. 2022 Sep 1;40(25):2924-2933. doi: <a href='https:\/\/doi.org\/10.1200\/JCO.21.02660' target='_blank'>10.1200\/JCO.21.02660<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35576508' target='_blank'>35576508<\/a><\/p>\n<p>Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Cancers. 2022 Feb 23;14(5):1146. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14051146' target='_blank'>10.3390\/cancers14051146<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35267454' target='_blank'>35267454<\/a><\/p>\n<p>Phase I trial of the DLL3\/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed Z, Liu M, Studeny M, Owonikoko T. Future Oncology. 2022 Aug;18(24):2639-2649. doi: <a href='https:\/\/doi.org\/10.2217\/fon-2022-0196' target='_blank'>10.2217\/fon-2022-0196<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35815644' target='_blank'>35815644<\/a><\/p>\n<p>Prognostic value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of rt-qpcr versus immunohistochemistry. Sanchez-Sendra B, Perez-Deben S, Gonzalez-Munoz JF, Murgui  A, Monteagudo C. Cancers. 2022 May 7;14(9):2319. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14092319' target='_blank'>10.3390\/cancers14092319<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35565448' target='_blank'>35565448<\/a><\/p>\n<p>Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network. Lopez-Guerrero J, Mendiola M, Perez-Fidalgo J, Romero I, Torres A, Recalde D, Molina E, Gomez-Raposo C, Levin A, Herrero A, Alarcon J, Esteban C, Marquina G, Rubio M, Guerra E, Sanchez-Lorenzo L, Galvez-Montosa F, de Juan A, Churruca C, Gallego A, Gonzalez-Martin A. Cancers. 2022 Apr 13;14(8):1965. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14081965' target='_blank'>10.3390\/cancers14081965<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35454870' target='_blank'>35454870<\/a><\/p>\n<p>Quality of life in cancer survivorship: Sociodemographic and disease-related moderators. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. European Journal of Cancer Care. 2022 Nov;31(6):e13692. doi: <a href='https:\/\/doi.org\/10.1111\/ecc.13692' target='_blank'>10.1111\/ecc.13692<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36069249' target='_blank'>36069249<\/a><\/p>\n<p>RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. Cancers. 2022 Dec 22;15(1):69. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15010069' target='_blank'>10.3390\/cancers15010069<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36612065' target='_blank'>36612065<\/a><\/p>\n<p>Safety and efficacy of dostarlimab in patients with recurrent\/advanced non-small cell lung cancer: results from cohort e of the Phase I GARNET Trial. Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Clinical Lung Cancer. 2022 Nov;23(7):e415-e427. doi: <a href='https:\/\/doi.org\/10.1016\/j.cllc.2022.05.013' target='_blank'>10.1016\/j.cllc.2022.05.013<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35729005' target='_blank'>35729005<\/a><\/p>\n<p>SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty COVID-19 vaccine. Gimenez E, Albert E, Zulaica J, Torres I, Rusu L, Rodriguez Moreno A, Burgos JS, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzales Candelas F, Geller R, Navarro D. Clinical Infectious Diseases. 2022 Aug 24;75(1):e865-e868. doi: <a href='https:\/\/doi.org\/10.1093\/cid\/ciac223' target='_blank'>10.1093\/cid\/ciac223<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35314856' target='_blank'>35314856<\/a><\/p>\n<p>SEOM-GEICO clinical guidelines on endometrial cancer (2021). Barretina Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, Perez Fidalgo JA, Romero I, Santaballa A, Rubio Perez MJ. Clinical &#038; Translational Oncology. 2022 Apr;24(4):625-634. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02799-7' target='_blank'>10.1007\/s12094-022-02799-7<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35312947' target='_blank'>35312947<\/a><\/p>\n<p>SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Capdevila J, Gomez M, Guillot M, Paez D, Pericay C, Safont M, Tarazona N, Vera R, Vidal J, Sastre J. Clinical &#038; Translational Oncology. 2022 Jul;24(7):1443-1444. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02855-2' target='_blank'>10.1007\/s12094-022-02855-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35596046' target='_blank'>35596046<\/a><\/p>\n<p>SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. Clinical &#038; Translational Oncology. 2022 Apr;24(4):646-657. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02816-9' target='_blank'>10.1007\/s12094-022-02816-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35303269' target='_blank'>35303269<\/a><\/p>\n<p>Short-term outcomes of colorectal cancer surgery in older patients: a novel nomogram predicting postoperative morbi-mortality. Moro-Valdezate D, Martin-Arevalo J, Ferro-Echevarria O, Pla-Marti V, Garcia-Botello S, Perez-Santiago L, Gadea-Mateo R, Tarazona N, Roda D, Rosello-Keranen S, Espi-Macias A. Langenbeck&#8217;s Archives of Surgery. 2022 Dec;407(8):3587-3597. doi: <a href='https:\/\/doi.org\/10.1007\/s00423-022-02688-1' target='_blank'>10.1007\/s00423-022-02688-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36129528' target='_blank'>36129528<\/a><\/p>\n<p>SMG8\/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Cancer Research. 2022 Nov 2;82(21):3962-3973. doi: <a href='https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4339' target='_blank'>10.1158\/0008-5472.CAN-21-4339<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36273494' target='_blank'>36273494<\/a><\/p>\n<p>SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: <a href='https:\/\/doi.org\/10.2217\/fon-2022-0660' target='_blank'>10.2217\/fon-2022-0660<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36200668' target='_blank'>36200668<\/a><\/p>\n<p>Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors. Rivas EI, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Bardia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis RR, Albanell J, Calon A. Nature Communications. 2022 Sep 9;13(1):5310. doi: <a href='https:\/\/doi.org\/10.1038\/s41467-022-32782-3' target='_blank'>10.1038\/s41467-022-32782-3<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36085201' target='_blank'>36085201<\/a><\/p>\n<p>The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O&#8217;Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: <a href='https:\/\/doi.org\/10.1186\/s12885-022-09689-9' target='_blank'>10.1186\/s12885-022-09689-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35692051' target='_blank'>35692051<\/a><\/p>\n<p>The prognostic value of miR-125b, miR-200c and miR-205 in primary cutaneous malignant melanoma is independent of BRAF mutational status. Sanchez-Sendra B, Gonzalez-Munoz J, Perez-Deben S, Monteagudo C. Cancers. 2022 Mar 16;14(6):1532. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14061532' target='_blank'>10.3390\/cancers14061532<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35326682' target='_blank'>35326682<\/a><\/p>\n<p>Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe R, Vinolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. Journal for Immunotherapy of Cancer. 2022 Sep;10(9):e005320. doi: <a href='https:\/\/doi.org\/10.1136\/jitc-2022-005320' target='_blank'>10.1136\/jitc-2022-005320<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36171009' target='_blank'>36171009<\/a><\/p>\n<p>Veliparib plus carboplatin and paclitaxel versus investigator&#8217;s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Clinical Lung Cancer. 2022 May;23(3):214-225. doi: <a href='https:\/\/doi.org\/10.1016\/j.cllc.2022.01.005' target='_blank'>10.1016\/j.cllc.2022.01.005<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35331641' target='_blank'>35331641<\/a><\/p>\n<p>Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Insa A, Martin-Martorell P, Di Liello R, Fasano M, Martini G, Napolitano S, Vicidomini G, Cappabianca S, Franco R, Morgillo F, Della Corte CM. Critical Reviews in Oncology\/Hematology. 2022 Jan;169:103538. doi: <a href='https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103538' target='_blank'>10.1016\/j.critrevonc.2021.103538<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34801700' target='_blank'>34801700<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-752522ae5177bef6cb6\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2021\" href=\"#tab-752522ae5177bef6cb6\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2021\" id=\"tab-752522ae5177bef6cb6\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nA phase Ib\/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced\/metastatic breast cancer. Schmid P, Sablin M, Bergh J, Im S, Lu Y, Martinez N, Neven P, Lee K, Morales S, Perez-Fidalgo J, Adamson D, Goncalves A, Prat A, Jerusalem G, Schlieker L, Espadero R, Bogenrieder T, Huang D, Crown J, Cortes J. Breast Cancer Research. 2021 Jan 15;23(1):8. doi: <a href='https:\/\/doi.org\/10.1186\/s13058-020-01382-8' target='_blank'>10.1186\/s13058-020-01382-8<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33451345' target='_blank'>33451345<\/a><\/p>\n<p>Alvarez NH,Bauer D,Hern\u00e1ndez J,Lewis JS. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem. 2021. 16(19):p. 2909-2941. IF:3,540. (3). <\/p>\n<p>Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia J, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Jul 24;6(5):100237. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100237' target='_blank'>10.1016\/j.esmoop.2021.100237<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411971' target='_blank'>34411971<\/a><\/p>\n<p>Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. ESMO open. 2021 Apr 19;6(3):100117. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100117' target='_blank'>10.1016\/j.esmoop.2021.100117<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33887690' target='_blank'>33887690<\/a><\/p>\n<p>Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Laza-Briviesca R, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo M, Huidobro G, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno J, Cobo M, Vivanco G, Del Barco E, Caro R, Vinolas N, Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarin C, Garcia-Grande A, Haymaker C, Wistuba I, Romero A, Franco F, Provencio M. Clinical and Translational Medicine. 2021 Jul;11(7):e491. doi: <a href='https:\/\/doi.org\/10.1002\/ctm2.491' target='_blank'>10.1002\/ctm2.491<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34323406' target='_blank'>34323406<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7384-4 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7384-4 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7384-4.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7384-4 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7384-4 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7384-4 .panel-title a:hover, #accordion-7384-4 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7384-4 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7384-4 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7384-4\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"da8b62cb01d6862a5\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7384-4\" data-target=\"#da8b62cb01d6862a5\" href=\"#da8b62cb01d6862a5\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2021<\/span><\/a><\/h4><\/div><div id=\"da8b62cb01d6862a5\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nBraga M,Leow CH,Gil JH,Teh JH,Carroll L,Long NJ,Tang MX,Aboagye EO. Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach. PLoS One. 2021. 16. (11):e0260186. IF:3,752. (2). <\/p>\n<p>Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant\u00a0therapy. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May;32(5):590-599. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.02.004' target='_blank'>10.1016\/j.annonc.2021.02.004<\/a>. Epub 2021 Feb 17. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33609722' target='_blank'>33609722<\/a><\/p>\n<p>Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: <a href='https:\/\/doi.org\/10.3390\/cancers13050994' target='_blank'>10.3390\/cancers13050994<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33673558' target='_blank'>33673558<\/a><\/p>\n<p>Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Journal for ImmunoTherapy of Cancer. 2021 Aug;9(8):e002804. doi: <a href='https:\/\/doi.org\/10.1136\/jitc-2021-002804' target='_blank'>10.1136\/jitc-2021-002804<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34446577' target='_blank'>34446577<\/a><\/p>\n<p>Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Lambertini M, Ceppi M, Hamy A, Caron O, Poorvu P, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Perez-Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Duhoux F, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Ferreira A, Partridge A, Di Meglio A, Saule C, Peccatori F, Bruzzone M, t&#8217;Kint de Roodenbeke M, Ameye L, Balmana J, Del Mastro L, Azim H. NPJ breast cancer. 2021 Feb 12;7(1):16. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-021-00224-w' target='_blank'>10.1038\/s41523-021-00224-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33579978' target='_blank'>33579978<\/a><\/p>\n<p>Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Oct;36(5):1124-1128. doi: <a href='https:\/\/doi.org\/10.1007\/s13187-020-01744-y' target='_blank'>10.1007\/s13187-020-01744-y<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32303982' target='_blank'>32303982<\/a><\/p>\n<p>Clinicians&#8217; attitude to doublet plus Anti-EGFR versus triplet plus bevacizumab as first-line treatment in left-sided RAS and BRAF wild-type metastatic colorectal cancer patients: a multicenter, &#8220;real-life&#8221;, case-control study. Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell&#8217;Aquila E, Claudia F, Lombardi P, Keranen S, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro F, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli G, Zoratto F, Roberto M, Ierino D, Petrillo A, D&#8217;Orazio C, Ficorella C, Cortellini A. Clinical Colorectal Cancer. 2021 Dec;20(4):318-325. doi: <a href='https:\/\/doi.org\/10.1016\/j.clcc.2021.07.003' target='_blank'>10.1016\/j.clcc.2021.07.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34380594' target='_blank'>34380594<\/a><\/p>\n<p>Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Romero A, Jantus-Lewintre E, Garcia-Pelaez B, Royuela A, Insa A, Cruz P, Collazo A, Altozano J, Vidal O, Diz P, Cobo M, Hernandez B, Estevez S, Benitez G, Guirado M, Majem M, Bernabe R, Ortega A, Blasco A, Bosch-Barrera J, Jurado J, Gonzalez J, Viteri S, Giron C, Massuti B, Martin A, Rodriguez-Festa A, Calabuig-Farinas S, Molina-Vila M, Provencio M. Molecular Oncology. 2021 Jan;15(1):43-56. doi: <a href='https:\/\/doi.org\/10.1002\/1878-0261.12832' target='_blank'>10.1002\/1878-0261.12832<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33107189' target='_blank'>33107189<\/a><\/p>\n<p>Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100285' target='_blank'>10.1016\/j.esmoop.2021.100285<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34752996' target='_blank'>34752996<\/a><\/p>\n<p>Cutaneous lymphadenoma is a distinct trichoblastoma-like lymphoepithelial tumor with diffuse androgen receptor immunoreactivity, notch1 ligand in reed-sternberg-like cells, and common EGFR somatic mutations. Monteagudo C, Funez R, Sanchez-Sendra B, Gonzalez-Munoz JF, Nieto G, Alfaro-Cervello C, Murgui A, Barr R. The American Journal of Surgical Pathology. 2021 Oct 1;45(10):1382-1390. doi: <a href='https:\/\/doi.org\/10.1097\/PAS.0000000000001727' target='_blank'>10.1097\/PAS.0000000000001727<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34232601' target='_blank'>34232601<\/a><\/p>\n<p>Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, Perez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-Garcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, Marti-Bonmati L. Alimentary Pharmacology &#038; Therapeutics. 2021 Jan;53(1):160-171. doi: <a href='https:\/\/doi.org\/10.1111\/apt.16100' target='_blank'>10.1111\/apt.16100<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32981113' target='_blank'>32981113<\/a><\/p>\n<p>Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Kaminska K, Akrap N, Staaf J, Alves C, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg A, Perez-Fidalgo A, Ditzel H, Bosch A, Honeth G. Breast Cancer Research. 2021 Feb 18;23(1):26. doi: <a href='https:\/\/doi.org\/10.1186\/s13058-021-01402-1' target='_blank'>10.1186\/s13058-021-01402-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33602273' target='_blank'>33602273<\/a><\/p>\n<p>Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Riudavets M, Bosch-Barrera J, Cabezon-Gutierrez L, Tain P, Hernandez A, Alonso M, Blanco R, Galvez E, Insa A, Mielgo X, Moran T, Ponce S, Roa D, Sanchez J, Majem M. Clinical &#038; Translational Oncology. 2021 Dec;23(12):2560-2567. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-021-02661-2' target='_blank'>10.1007\/s12094-021-02661-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34292495' target='_blank'>34292495<\/a><\/p>\n<p>Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: <a href='https:\/\/doi.org\/10.3390\/cancers13061433' target='_blank'>10.3390\/cancers13061433<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33801071' target='_blank'>33801071<\/a><\/p>\n<p>ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.04.001' target='_blank'>10.1016\/j.annonc.2021.04.001<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34090547' target='_blank'>34090547<\/a><\/p>\n<p>ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jul;32(7):823-824. doi: 10.1016\/j.annonc.2021.04.001. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34144776' target='_blank'>34144776<\/a><\/p>\n<p>ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, Cervantes A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Jun;36(3):556-560. doi: <a href='https:\/\/doi.org\/10.1007\/s13187-019-01664-6' target='_blank'>10.1007\/s13187-019-01664-6<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/31845109' target='_blank'>31845109<\/a><\/p>\n<p>First-in-human phase I study of a next-generation, oral, transforming growth factor-beta receptor 1 inhibitor, LY3200882 in patients with advanced cancer. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. Clinical Cancer Research. 2021 Dec 15;27(24):6666-6676. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1504' target='_blank'>10.1158\/1078-0432.CCR-21-1504<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34548321' target='_blank'>34548321<\/a><\/p>\n<p>First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, Spanish Cooperative Grp Treatment. Drugs &#038; Aging. 2021 Mar;38(3):219-231. doi: <a href='https:\/\/doi.org\/10.1007\/s40266-021-00834-w' target='_blank'>10.1007\/s40266-021-00834-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33615402' target='_blank'>33615402<\/a><\/p>\n<p>Folliculotropic mycosis fungoides with flexural eruptive cysts and comedones in a 14-year-old boy. Roca-Gines J, Alfaro-Cervello C, Sanchez-Arraez J, Torres-Navarro I, Navarro-Mira MA, Monteagudo C, Botella-Estrada R. American Journal of Dermatopathology. 2021 Sep 1;43(9):656-658. doi: <a href='https:\/\/doi.org\/10.1097\/DAD.0000000000001958' target='_blank'>10.1097\/DAD.0000000000001958<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33989213' target='_blank'>33989213<\/a><\/p>\n<p>Gonzales J,Hern\u00e1ndez J,Wilson TC,Adilbay D,Cornejo M,Franca PDD,Guru N,Schroeder CI,King GF,Lewis JS,Reiner T. Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers. Mol. Pharm. 2021. 18. (3):p. 940-951. IF:5,364. (1). <\/p>\n<p>Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: <a href='https:\/\/doi.org\/10.1016\/j.ccell.2021.03.004' target='_blank'>10.1016\/j.ccell.2021.03.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33798472' target='_blank'>33798472<\/a><\/p>\n<p>Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). Jimenez-Labaig P, Pacheco-Barcia V, Cebria A, Galvez F, Obispo B, Paez D, Quilez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sanchez D, Sanchez-Canovas M, Sanz-Garcia E, Sesma A, Tarazona N, Cotes A, Gonzalez E, Bosch-Barrera J, Fernandez A, Felip E, Vera R, Rodriguez-Lescure A, Elez E. ESMO Open. 2021 Jul 26;6(4):100215. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100215' target='_blank'>10.1016\/j.esmoop.2021.100215<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34325108' target='_blank'>34325108<\/a><\/p>\n<p>In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100116' target='_blank'>10.1016\/j.esmoop.2021.100116<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33887688' target='_blank'>33887688<\/a><\/p>\n<p>In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100247' target='_blank'>10.1016\/j.esmoop.2021.100247<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411970' target='_blank'>34411970<\/a><\/p>\n<p>In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2020.100009' target='_blank'>10.1016\/j.esmoop.2020.100009<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33399075' target='_blank'>33399075<\/a><\/p>\n<p>In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100061' target='_blank'>10.1016\/j.esmoop.2021.100061<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33639602' target='_blank'>33639602<\/a><\/p>\n<p>In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100186' target='_blank'>10.1016\/j.esmoop.2021.100186<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34098228' target='_blank'>34098228<\/a><\/p>\n<p>LungBEAM: a prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Garrido P, Paz-Ares L, Majem M, Moran T, Trigo JM, Bosch-Barrera J, Garcia-Campelo R, Gonzalez-Larriba JL, Sanchez-Torres JMiguel, Isla D, Vinolas N, Camps C, Insa A, Juan O, Massuti B, Paredes A, Artal A, Lopez-Brea M, Palacios J, Felip E. Cancer Medicine. 2021 Sep;10(17):5878-5888. doi: <a href='https:\/\/doi.org\/10.1002\/cam4.4135' target='_blank'>10.1002\/cam4.4135<\/a>.PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34296539' target='_blank'>34296539<\/a><\/p>\n<p>Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-021-01502-x' target='_blank'>10.1038\/s41416-021-01502-x<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34493820' target='_blank'>34493820<\/a><\/p>\n<p>Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phaseII trial (ROLANDO study). Perez-Fidalgo J, Cortes A, Guerra E, Garcia Y, Iglesias M, Bohn Sarmiento U, Calvo Garcia E, Manso Sanchez L, Santaballa A, Oaknin A, Redondo A, Rubio M, Gonzalez-Martin A. ESMO Open. 2021 Jul 27;6(4):100212. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100212' target='_blank'>10.1016\/j.esmoop.2021.100212<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34329939' target='_blank'>34329939<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1752' target='_blank'>10.1016\/j.annonc.2021.08.1752<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411693' target='_blank'>34411693<\/a><\/p>\n<p>Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Oct;47(10):2697. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejso.2021.06.031' target='_blank'>10.1016\/j.ejso.2021.06.031<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34217579' target='_blank'>34217579<\/a><\/p>\n<p>Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with\u00a0PIK3CA-Mutant Cancers. Jhaveri K, Chang M, Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Clinical Cancer Research. 2021 Jan 15;27(2):447-459. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2657' target='_blank'>10.1158\/1078-0432.CCR-20-2657<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33148674' target='_blank'>33148674<\/a><\/p>\n<p>Post-induction management in patients with left-sided\u00a0RAS\u00a0and\u00a0BRAF\u00a0wild-type metastatic colorectal cancer treated with first-line anti-egfr-based doublet regimens: a multicentre study. Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Rosell\u00f3 Ker\u00e4nen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D&#8217;Orazio C, Ficorella C, Ferri C, Porzio G. Frontiers in Oncology. 2021 Oct 27;11:712053. doi: <a href='https:\/\/doi.org\/10.3389\/fonc.2021.712053' target='_blank'>10.3389\/fonc.2021.712053<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34778029' target='_blank'>34778029<\/a><\/p>\n<p>Postoperative ctDNA monitoring: a canary in a coalmine. Lumish M, Tarazona N, Janjigian Y. Annals of oncology. 2021 Apr;32(4):431-433. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.01.005' target='_blank'>10.1016\/j.annonc.2021.01.005<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33484835' target='_blank'>33484835<\/a><\/p>\n<p>Potential biomarkers associated with multiple sclerosis pathology. Mathur D, Mishra BK, Rout S, Lopez-Iranzo FJ, Lopez-Rodas G, Vallamkondu J, Kandimalla R, Casanova B. International Journal of Molecular Sciences. 2021 Sep 25;22(19):10323. doi: <a href='https:\/\/doi.org\/10.3390\/ijms221910323' target='_blank'>10.3390\/ijms221910323<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34638664' target='_blank'>34638664<\/a><\/p>\n<p>Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo R, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba I, Romero A, Calvo V, Provencio M. Clinical Cancer Research. 2021 Nov 1;27(21):5878-5890. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1200' target='_blank'>10.1158\/1078-0432.CCR-21-1200<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34376534' target='_blank'>34376534<\/a><\/p>\n<p>Prognostic implications of surgical specimen quality on the oncological outcomes of open and laparoscopic surgery in mid and low rectal cancer. Pla-Marti V, Martin-Arevalo J, Moro-Valdezate D, Garcia-Botello S, Perez-Santiago L, Lapena-Rodriguez M, Bauza-Collado M, Huerta M, Rosello-Keranen S, Espi-Macias A. Langenbeck&#8217;s archives of surgery. 2021 Dec;406(8):2759-2767. doi: <a href='https:\/\/doi.org\/10.1007\/s00423-021-02351-1' target='_blank'>10.1007\/s00423-021-02351-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34716825' target='_blank'>34716825<\/a><\/p>\n<p>Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2021.102263' target='_blank'>10.1016\/j.ctrv.2021.102263<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34343892' target='_blank'>34343892<\/a><\/p>\n<p>Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.05.795' target='_blank'>10.1016\/j.annonc.2021.05.795<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34033882' target='_blank'>34033882<\/a><\/p>\n<p>Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosell\u00f2 S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Sep;20(3):227-235. doi: <a href='https:\/\/doi.org\/10.1016\/j.clcc.2021.06.002' target='_blank'>10.1016\/j.clcc.2021.06.002<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34226142' target='_blank'>34226142<\/a><\/p>\n<p>Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1\/2 with a pregnancy after prior history of breast cancer. Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Cordoba O, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, Perez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmana J, Partridge AH, Azim HA, Demeestere I, Lambertini M. ESMO Open. 2021 Nov 11;6(6):100300. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100300' target='_blank'>10.1016\/j.esmoop.2021.100300<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34775302' target='_blank'>34775302<\/a><\/p>\n<p>SEOM clinical guideline in ovarian cancer (2020). Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio M, Barretina-Ginesta M, Gonzalez-Martin A. Clinical &#038; translational oncology. 2021 May;23(5):961-968. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-020-02545-x' target='_blank'>10.1007\/s12094-020-02545-x<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33515422' target='_blank'>33515422<\/a><\/p>\n<p>Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: <a href='https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6' target='_blank'>10.1016\/S1470-2045(20)30555-6<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33301740' target='_blank'>33301740<\/a><\/p>\n<p>Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemotherapy and Pharmacology. 2021 Dec;88(6):921-930. doi: <a href='https:\/\/doi.org\/10.1007\/s00280-021-04344-9' target='_blank'>10.1007\/s00280-021-04344-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34471960' target='_blank'>34471960<\/a><\/p>\n<p>Teh JH,Braga M,Allott L,Barnes C,Hernandez J,Tang MX,Aboagye EO,Long N. A kit-based aluminium-[<SUP>18<\/SUP>F]fluoride approach to radiolabelled microbubbles. Chem. Commun. 2021. 57. (88):p. 11677-11680. IF:6,065. (2). <\/p>\n<p>Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100148' target='_blank'>10.1016\/j.esmoop.2021.100148<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33989988' target='_blank'>33989988<\/a><\/p>\n<p>The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies. Cervantes A. ESMO Open. 2021 Jun;6(3):100169. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100169' target='_blank'>10.1016\/j.esmoop.2021.100169<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34144777' target='_blank'>34144777<\/a><\/p>\n<p>Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective  analysis and critical assessment of a 10-year prospective national registry on  behalf of the Spanish Rectal Cancer Project. Pellino G, Al\u00f3s R, Biondo S, Codina-Cazador A, Enr\u00edquez-Navascues J, Esp\u00edn-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejso.2020.04.056' target='_blank'>10.1016\/j.ejso.2020.04.056<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32950316' target='_blank'>32950316<\/a><\/p>\n<p>Unexpected finding of iIntravascular large B-cell lymphoma by a skin biopsy. Guillen-Climent S, Garcia-Vazquez A, Martinez-Ciarpaglini C. Medicina Clinica. 2021 Aug 13;157(3):151-152. doi: <a href='https:\/\/doi.org\/10.1016\/j.medcli.2020.04.051' target='_blank'>10.1016\/j.medcli.2020.04.051<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32951879' target='_blank'>32951879<\/a><\/p>\n<p>Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014' target='_blank'>10.1016\/j.annonc.2021.02.014<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33716105' target='_blank'>33716105<\/a><\/p>\n<p>Using DNA sequencing data to quantify T cell fraction and therapy response. Bentham R, Litchfield K, Watkins T, Lim E, Rosenthal R, Martinez-Ruiz C, Hiley C, Al Bakir M, Salgado R, Moore D, Jamal-Hanjani M, Swanton C, McGranahan N, TRACERx Consortium. Nature. 2021 Sep;597(7877):555-560. doi: <a href='https:\/\/doi.org\/10.1038\/s41586-021-03894-5' target='_blank'>10.1038\/s41586-021-03894-5<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34497419' target='_blank'>34497419<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-12{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-12 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-12{width:100% !important;}.fusion-builder-column-12 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-12{width:100% !important;}.fusion-builder-column-12 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-4{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-5 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #9da0d2;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-16\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: left;\">Projects<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-2 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-2 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-2 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav,.fusion-tabs.fusion-tabs-2 .nav-tabs,.fusion-tabs.fusion-tabs-2 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-58dd943db15ee99923d\" aria-selected=\"true\" id=\"fusion-tab-projects\" href=\"#tab-58dd943db15ee99923d\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-58dd943db15ee99923d\" aria-selected=\"true\" id=\"mobile-fusion-tab-projects\" href=\"#tab-58dd943db15ee99923d\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-projects\" id=\"tab-58dd943db15ee99923d\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:left;\">\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>101095359 &#8211; AIDA<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>An Artificially Intelligent Diagnostic Assistant for gastric inflammation. AIDA<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Tania Fleitas Kanonnikoff<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2023 &#8211; 2026<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>1,138,750 (Total: 6,334,803.75)\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI22\/01173<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>El papel del estr\u00e9s oxidativo y la v\u00eda NRF2 en determinar resistencia a quimioinmunoterapia de primera l\u00ednea en pacientes con c\u00e1ncer de pulm\u00f3n no microcitico avanzado KRAS mutado<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Valentina Gambardella<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2023 &#8211; 2025<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>111.320 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI22\/02000<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Hacia la medicina de precisi\u00f3n en el colangiocarcinoma: la relevancia de la radiogen\u00f3mica que define el perfil molecular de un paciente individual en busca de nuevas oportunidades de tratamiento<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Desamparados Roda P\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2023 &#8211; 2025<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>98.494 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>101057514 &#8211; Mypath<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Developing and implementing innovative Patient-Centred Care Pathways for cancer patients<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2027<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>388,125 (Total: 4,773,470.00)\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI21\/00695<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Transici\u00f3n mesenquimal como mecanismo asociado a inhibici\u00f3n de la respuesta inmune en el carcinoma colorrectal sin inestabilidad de microsat\u00e9lites<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>M\u00aa Carolina Mart\u00ednez Ciarpaglini<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>94.380 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI21\/00693<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Perfil de biomarcadores inmunes como herramienta para la identificaci\u00f3n de pacientes con c\u00e1ncer g\u00e1stricos subsidiarios de inmunoterapia<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Tania Fleitas Kanonnikoff<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>208.120 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI21\/00689<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Caracterizaci\u00f3n y abordaje de la enfermedad m\u00ednima residual en c\u00e1ncer de colon localizado: un paso hacia la medicina de precisi\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Noelia Tarazona Llavero, Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>232.320 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>CPP2021-009064<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Tratamiento innovador con ABTL0812 para el cancer pancre\u00e1tico metast\u00e1tico: acortando los tiempos para su aprobaci\u00f3n \u2013 INNOPANC<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Ministerio de Ciencia e Innovaci\u00f3n \u2013 Agencia Estatal de Investigaci\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Carles Domenech Garc\u00eda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>180.599 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>GV\/2021\/006<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Subvenci\u00f3n a grupos de Investigaci\u00f3n emergentes<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Clara Alfaro Cervell\u00f3<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>20.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI-2021-007<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>DIRUGEN: Dise\u00f1o e investigaci\u00f3n de nuevos compuestos de rutenio (III) basados en biomol\u00e9culas como potenciales agentes antitumorales<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Universidad de Valencia &#8211; INCLIVA<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Francisco Jos\u00e9 Mart\u00ednez Lillo, Tania Fleitas Kanonnikoff<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>19.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>AP-2021-008<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>PROTORGANOIDE: Medicina personalizada y de precisi\u00f3n a trav\u00e9s del an\u00e1lisis prote\u00f3mico de organoides<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Universidad de Valencia &#8211; INCLIVA<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Manuel Mart\u00edn S\u00e1nchez del Pino, Josefa Castillo Aliaga<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>4.750 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>ICI20\/00009<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Investigaci\u00f3n Cl\u00ednica Independiente<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>1.039.970 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PT20\/00100<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Plataforma de Investigaci\u00f3n Cl\u00ednica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>199.650 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>GV\/2020\/189<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Estudio de la carga tumoral ganglionar y el budding tumoral como factores pron\u00f3sticos el c\u00e1ncer colorrectal en estadios localizados<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Conselleria de Educaci\u00f3n, Cultura y Deporte<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>M\u00aa Carolina Mart\u00ednez Ciarpaglini<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2020 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>16.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>825832 \u2013 LEGACy<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>CeLac and European consortium for a personalized medicine approach to Gastric Cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>\u20ac3.577.431,27 (INCLIVA: \u20ac638.315)\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI18\/01508<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Macr\u00f3fagos asociados al tumor, angiog\u00e9nesis tumoral y resistencia a las terapias en C\u00e1ncer G\u00e1strico Difuso fenotipo Mesenquimal<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Tania Carolina Fleitas Kanonnikoff<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>99.220 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI18\/01909<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Medicina personalizada en pacientes con c\u00e1ncer colorrectal localizado: abordaje multi\u00f3mico de la Enfermedad M\u00ednima Residual en biopsia l\u00edquida y modelos de organoides<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez, Desamparados Roda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>141.570 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PT17\/0017\/0003<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Plataforma de Investigaci\u00f3n y Ensayos Cl\u00ednicos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2018 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>266.475 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>CB16\/12\/00473<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>CIBER Oncolog\u00eda (CIBERONC)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2017 &#8211;<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI16\/00393<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>De la gen\u00f3mica del c\u00e1ncer a la inmuno-oncologia. B\u00fasqueda de biomarcadores de respuesta a la inmunoterapia anti-PD1\/PDL1 en c\u00e1ncer mediante una aproximaci\u00f3n de biolog\u00eda de sistemas<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Joan Climent Bataller<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2017 &#8211; 2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>98.615 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>AC15\/00096<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and apigenetic study of intratumoral herterogeneity dynamics<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission (Programaci\u00f3n conjunta internacional ISCIII)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2016 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>29.645 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>MoTriColor<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Josep Tabernero<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2015 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>271.424 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>FERP-2024-153<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo de Radiof\u00e1rmacos Espec\u00edficos del Receptor de Tirosina Quinasa AXL: Avances en el Tratamiento del C\u00e1ncer de Mama.<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>FUNDACION EUGENIO RODRIGUEZ PASCUAL<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>JAVIER HERN\u00c1NDEZ GIL; CEJALVO ANDUJAR, JUAN MIGUEL; CERVANTES RUIPEREZ, ANDR\u00c9S<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span> &#8211;<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>0 \u20ac\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-13{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-13 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-13{width:100% !important;order : 0;}.fusion-builder-column-13 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-13{width:100% !important;order : 0;}.fusion-builder-column-13 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-5{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-6 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-17\" style=\"transform:translate3d(0,0,0);\"><h5>+ Info<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-3 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-3 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-3 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav,.fusion-tabs.fusion-tabs-3 .nav-tabs,.fusion-tabs.fusion-tabs-3 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-616ffcb9e0c51e85585\" aria-selected=\"true\" id=\"fusion-tab-clinicalguides\" href=\"#tab-616ffcb9e0c51e85585\"><h4 class=\"fusion-tab-heading\">CLINICAL GUIDES<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-685280f3ceb54dcbe9f\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-thesis\" href=\"#tab-685280f3ceb54dcbe9f\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-616ffcb9e0c51e85585\" aria-selected=\"true\" id=\"mobile-fusion-tab-clinicalguides\" href=\"#tab-616ffcb9e0c51e85585\"><h4 class=\"fusion-tab-heading\">CLINICAL GUIDES<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-clinicalguides\" id=\"tab-616ffcb9e0c51e85585\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023). Garcia-Campelo R, Sullivan I, Arriola E, Insa A, Vidal O, Cruz-Castellanos P, Moran T, Reguart N, Zugazagoitia J, Domine M. Clinical &#038; Translational Oncology. 2023 Sep;25(9):2760-2762. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-023-03290-7' target='_blank'>10.1007\/s12094-023-03290-7<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37556098' target='_blank'>37556098<\/a><\/p>\n<p>SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Garcia-Campelo R, Sullivan I, Arriola E, Insa A, Juan Vidal O, Cruz-Castellanos P, Moran T, Reguart N, Zugazagoitia J, Domine M. Clinical &#038; Translational Oncology. 2023 Sep;25(9):2679-2691. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-023-03216-3' target='_blank'>10.1007\/s12094-023-03216-3<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37418123' target='_blank'>37418123<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101558' target='_blank'>10.1016\/j.esmoop.2023.101558<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37236086' target='_blank'>37236086<\/a><\/p>\n<p>Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Perez-Fidalgo J, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Verdum J, de Alava E, Lopez M, Marquina G, Sebio A. Therapeutic Advances in Medical Oncology. 2023 Mar 28;15:17588359231157645. doi: <a href='https:\/\/doi.org\/10.1177\/17588359231157645' target='_blank'>10.1177\/17588359231157645<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37007636' target='_blank'>37007636<\/a><\/p>\n<p>Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003' target='_blank'>10.1016\/j.annonc.2022.10.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36307056' target='_blank'>36307056<\/a><\/p>\n<p>Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003' target='_blank'>10.1016\/j.annonc.2022.07.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35914638' target='_blank'>35914638<\/a><\/p>\n<p>Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):1005-1020. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004' target='_blank'>10.1016\/j.annonc.2022.07.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35914639' target='_blank'>35914639<\/a><\/p>\n<p>SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Capdevila J, Gomez M, Guillot M, Paez D, Pericay C, Safont M, Tarazona N, Vera R, Vidal J, Sastre J. Clinical &#038; Translational Oncology. 2022 Jul;24(7):1443-1444. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02855-2' target='_blank'>10.1007\/s12094-022-02855-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35596046' target='_blank'>35596046<\/a><\/p>\n<p>SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. Clinical &#038; Translational Oncology. 2022 Apr;24(4):646-657. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02816-9' target='_blank'>10.1007\/s12094-022-02816-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35303269' target='_blank'>35303269<\/a><\/p>\n<p>SEOM-GEICO clinical guidelines on endometrial cancer (2021). Barretina Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, Perez Fidalgo JA, Romero I, Santaballa A, Rubio Perez MJ. Clinical &#038; Translational Oncology. 2022 Apr;24(4):625-634. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02799-7' target='_blank'>10.1007\/s12094-022-02799-7<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35312947' target='_blank'>35312947<\/a><\/p>\n<p>SEOM clinical guideline in ovarian cancer (2020). Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio M, Barretina-Ginesta M, Gonzalez-Martin A. Clinical &#038; translational oncology. 2021 May;23(5):961-968. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-020-02545-x' target='_blank'>10.1007\/s12094-020-02545-x<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33515422' target='_blank'>33515422<\/a><\/p>\n<p>Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014' target='_blank'>10.1016\/j.annonc.2021.02.014<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33716105' target='_blank'>33716105<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1752' target='_blank'>10.1016\/j.annonc.2021.08.1752<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411693' target='_blank'>34411693<\/a><\/p>\n<p>New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Rosell\u00f3 Ker\u00e4nen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2020.07.012' target='_blank'>10.1016\/j.annonc.2020.07.012<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32710931' target='_blank'>32710931<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2019.12.001' target='_blank'>10.1016\/j.annonc.2019.12.001<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32067677' target='_blank'>32067677<\/a><\/p>\n<p>Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balma\u00f1a J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: <a href='https:\/\/doi.org\/10.1093\/annonc\/mdz233' target='_blank'>10.1093\/annonc\/mdz233<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/31378807' target='_blank'>31378807<\/a><\/p>\n<p>Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A,\u00a0Cervantes A,\u00a0Chau I,\u00a0Daniele B,\u00a0Llovet JM,\u00a0Meyer T,\u00a0Nault JC,\u00a0Neumann U,\u00a0Ricke J,\u00a0Sangro B,\u00a0Schirmacher P,\u00a0Verslype C,\u00a0Zech CJ,\u00a0Arnold D,\u00a0Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: <a href='https:\/\/doi.org\/10.1093\/annonc\/mdy510' target='_blank'>10.1093\/annonc\/mdy510<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/30715202' target='_blank'>30715202<\/a><\/p>\n<p>SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Majem M,\u00a0Juan O,\u00a0Insa A,\u00a0Reguart N,\u00a0Trigo JM,\u00a0Carcereny E,\u00a0Garc\u00eda-Campelo R,\u00a0Garc\u00eda Y,\u00a0Guirado M,\u00a0Provencio M. Clinical &#038; Translational Oncology. 2019 Jan;21(1):3-17. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-018-1978-1' target='_blank'>10.1007\/s12094-018-1978-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/30446985' target='_blank'>30446985<\/a><\/p>\n<\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-685280f3ceb54dcbe9f\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-thesis\" href=\"#tab-685280f3ceb54dcbe9f\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-thesis\" id=\"tab-685280f3ceb54dcbe9f\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\"><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Tecnolog\u00edas de secuenciaci\u00f3n masiva y PCR digital en la detecci\u00f3n de ADN tumoral procedente de tejido y plasma en pacientes de colon localizado<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>T\u00e9bar Mart\u00ednez, Roberto<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Rentero Garrido, Pilar; Cervantes Ruip\u00e9rez, Andr\u00e9s; Tarazona Llavero, Noelia<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>01\/02\/2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Establecimiento de organoides derivados de pacientes con carcinoma colorrectal como modelo para cribado de drogas con acci\u00f3n antitumoral<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Guti\u00e9rrez Bravo, M\u00aa Fernanda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Castillo Aliaga, Josefa; Cervantes Ruip\u00e9rez, Andr\u00e9s<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>04\/02\/2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Multi-omic characterization of advanced colorectal cancer patients derived organoids in the context of Precision Medicine<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Papaccio, Federica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Cervantes Ruip\u00e9rez, Andr\u00e9s; Castillo Aliaga, Josefa<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>23\/12\/2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universit\u00e0 della Campania Luigi Vanvitelli<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Role of EDPR1 and the ZNF518B factor in the development of colorectal cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Gimeno Valiente, Francisco<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Castillo Aliaga, Josefa; L\u00f3pez Rodas, Gerardo; Franco Vera Luis<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>03\/12\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Tarazona Llavero, Noelia<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Cervantes Ruip\u00e9rez, Andr\u00e9s<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>23\/07\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Genetic determinants of atr inhibitor sensitivity and resistance in gastric cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Llorca Carde\u00f1osa, Marta Jessica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Cervantes Ruip\u00e9rez, Andr\u00e9s; Ribas Despuig, Gloria<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>22\/07\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Study of the epi-\/genomic dysregulation of breast cancer in women under 35 years and evaluation of cellular models<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Oltra Sanchis, Sara<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Ribas Despuig, Gloria; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>18\/01\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-14{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-14 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-14{width:100% !important;order : 0;}.fusion-builder-column-14 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-14{width:100% !important;order : 0;}.fusion-builder-column-14 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-6{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":6408,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7384"}],"collection":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=7384"}],"version-history":[{"count":0,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7384\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/6408"}],"wp:attachment":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=7384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}